Latest Primary biliary cirrhosis Stories
LEXINGTON, Massachusetts, April 9, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the 13-week Phase 2 IMAGO trial of its investigational compound
GOTHENBURG, Sweden, February 5, 2015 /PRNewswire/ -- Albireo today announced initiation of a phase II trial with A4250, the company's lead compound for cholestatic liver
ReportsnReports.com adds “Biliary Cirrhosis - Pipeline Review, H2 2014” to its store.
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
CAMEO Phase 2 Clinical Trial of LUM001 Now Enrolling Adults with Primary Sclerosing Cholangitis SAN DIEGO, May 9, 2014 /PRNewswire/ --
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements.
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals